Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Innovative Medical |
---|---|
Information provided by: | Innovative Medical |
ClinicalTrials.gov Identifier: | NCT00477763 |
To compare the performance of Oasys to Extreme H20 xtra 59 in dry eye contact lens pts who receive Restasis in 1 eye and vehicle (Endura) in the other eye.
Condition | Intervention | Phase |
---|---|---|
Dry Eye |
Drug: Restasis, Refresh Endura |
Phase IV |
Study Type: | Interventional |
Study Design: | Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment |
Official Title: | Oasys vs. Extreme H20 Xtra 59 |
Enrollment: | 52 |
Study Start Date: | May 2007 |
Study Completion Date: | February 2008 |
Primary Completion Date: | February 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Active Comparator |
Drug: Restasis, Refresh Endura
|
2: Placebo Comparator |
Drug: Restasis, Refresh Endura
|
Ages Eligible for Study: | 19 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Pennsylvania | |
Hazleton Eye Specialists | |
Hazleton, Pennsylvania, United States, 18202 |
Principal Investigator: | Thomas Kislan, OD | Hazleton Eye Specialists |
Responsible Party: | Hazleton Eye Specialists ( Thomas Kislan, OD ) |
Study ID Numbers: | 5300 |
Study First Received: | May 21, 2007 |
Last Updated: | February 13, 2008 |
ClinicalTrials.gov Identifier: | NCT00477763 |
Health Authority: | Unitet States: Institutional Review Board |
Cyclosporine Clotrimazole Miconazole Tioconazole Cyclosporins |
Anti-Infective Agents Immunologic Factors Molecular Mechanisms of Pharmacological Action Therapeutic Uses Antifungal Agents Physiological Effects of Drugs |
Enzyme Inhibitors Antirheumatic Agents Immunosuppressive Agents Dermatologic Agents Pharmacologic Actions |